Optimization	optimization	O	O	O	O
of	of	O	O	O	O
levodopa	levodopa	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
.	.	O	O	O	O

While	while	O	O	O	O
there	there	O	O	O	O
is	is	O	O	O	O
no	no	O	O	O	O
single	single	O	O	O	O
correct	correct	O	O	O	O
starting	starting	O	O	O	O
dose	dose	O	O	O	O
for	for	O	O	O	O
levodopa	levodopa	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
,	,	O	O	O	O
many	many	O	O	O	O
individuals	individuals	O	O	O	O
can	can	O	O	O	O
be	be	O	O	O	O
started	started	O	O	O	O
on	on	O	O	O	O
either	either	O	O	O	O
the	the	O	O	O	O
25/100	25/100	O	O	O	O
or	or	O	O	O	O
controlled-release	controlled-release	O	O	O	O
formula	formula	O	O	O	O
,	,	O	O	O	O
following	following	O	O	O	O
the	the	O	O	O	O
general	general	O	O	O	O
rule	rule	O	O	O	O
not	not	O	O	O	O
to	to	O	O	O	O
attempt	attempt	O	O	O	O
to	to	O	O	O	O
titrate	titrate	O	O	O	O
carbidopa-levodopa	carbidopa-levodopa	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
point	point	O	O	O	O
of	of	O	O	O	O
"	"	O	O	O	O
normality	normality	O	O	O	O
,	,	O	O	O	O
"	"	O	O	O	O
which	which	O	O	O	O
can	can	O	O	O	O
lead	lead	O	O	OTHERS	I
to	to	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
physician	physician	O	O	O	O
should	should	O	O	O	O
also	also	O	O	O	O
determine	determine	O	O	O	O
the	the	O	O	O	O
proper	proper	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
any	any	O	O	O	O
adjunctive	adjunctive	O	O	O	O
medications	medications	O	O	O	O
;	;	O	O	O	O
such	such	O	O	O	O
combined	combined	O	O	O	O
therapy	therapy	O	O	O	O
has	has	O	O	O	O
become	become	O	O	O	O
the	the	O	O	O	O
standard	standard	O	O	O	O
approach	approach	O	O	O	O
to	to	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Following	following	O	O	O	O
the	the	O	O	O	O
initial	initial	O	O	O	O
period	period	O	O	O	O
of	of	O	O	O	O
therapy	therapy	O	O	O	O
,	,	O	O	O	O
emerging	emerging	O	O	O	O
difficulties	difficulties	O	O	O	O
require	require	O	O	O	O
a	a	O	O	O	O
reassessment	reassessment	O	O	O	O
of	of	O	O	O	O
therapeutic	therapeutic	O	O	O	O
approaches	approaches	O	O	O	O
,	,	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
dosage	dosage	O	O	O	O
adjustment	adjustment	O	O	O	O
or	or	O	O	O	O
introduction	introduction	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
agonist	agonist	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Other	other	O	O	O	O
possible	possible	O	O	O	O
adverse	adverse	O	O	O	O
effects	effects	O	O	O	O
--	--	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
gastrointestinal	gastrointestinal	O	O	OTHERS	I
disorders	disorders	O	O	OTHERS	I
,	,	O	O	O	O
orthostatic	orthostatic	O	DISEASE	OTHERS	I
hypotension	hypotension	O	DISEASE	OTHERS	I
,	,	O	O	O	O
levodopa-induced	levodopa-induced	O	O	O	O
psychosis	psychosis	O	DISEASE	OTHERS	I
,	,	O	O	O	O
sleep	sleep	O	O	OTHERS	I
disturbances	disturbances	O	O	OTHERS	I
or	or	O	O	O	O
parasomnias	parasomnias	O	O	OTHERS	I
,	,	O	O	O	O
or	or	O	O	O	O
drug	drug	O	O	O	O
interactions	interactions	O	O	O	O
--	--	O	O	O	O
also	also	O	O	O	O
require	require	O	O	O	O
carefully	carefully	O	O	O	O
monitored	monitored	O	O	O	O
individual	individual	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Nonpharmacologic	nonpharmacologic	O	O	O	O
concerns	concerns	O	O	O	O
can	can	O	O	O	O
help	help	O	O	O	O
the	the	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
patient	patient	O	O	O	O
achieve	achieve	O	O	O	O
and	and	O	O	O	O
maintain	maintain	O	O	O	O
optimal	optimal	O	O	O	O
functioning	functioning	O	O	O	O
,	,	O	O	O	O
including	including	O	O	O	O
daily	daily	O	O	O	O
exercise	exercise	O	O	O	O
,	,	O	O	O	O
physical	physical	O	O	O	O
therapy	therapy	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
involvement	involvement	O	O	O	O
with	with	O	O	O	O
support	support	O	O	O	O
groups	groups	O	O	O	O
.	.	O	O	O	O

